Zanubrutinib ( DrugBank: Zanubrutinib )

---

5 diseases

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	1
63	Idiopathic thrombocytopenic purpura	2
222	Primary nephrotic syndrome	1
300	IgG4-related disease	1
331	Idiopathic multicentric castleman disease	1

13. Multiple sclerosis/Neuromyelitis optica

---

Clinical trials : 3,340 /  Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05356858 (ClinicalTrials.gov)	May 7, 2022	26/4/2022	An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult Patients	An Open Label Trial Evaluating the Efficacy and Safety of Bruton's Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Adult Patients With Neuromyelitis Optical Spectrum Disorders (NMOSDs)	Neuromyelitis Optica	Drug: zanubrutinib	Xuanwu Hospital, Beijing	NULL	Recruiting	18 Years	75 Years	All	20	Phase 2	China

63. Idiopathic thrombocytopenic purpura

---

Clinical trials : 391 /  Drugs : 235 - (DrugBank : 50) / Drug target genes : 49 - Drug target pathways : 139

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2200057058	2022-07-01	2022-02-27	A Single-Arm Prospective Exploratory Clinical Study Of Zanubrutinib Combined With Rituximab In The Treatment Of Steroid-Ineffective Primary Immune Thrombocytopenia	A Single-Arm Prospective Exploratory Clinical Study Of Zanubrutinib Combined With Rituximab In The Treatment Of Steroid-Ineffective Primary Immune Thrombocytopenia	Primary Immune Thrombocytopenia	Therapy Group:Zanubrutinib (80 mg, 2 times/day, for a total of 12 weeks) combined with Rituximab (375 mg/m2, 1 intravenous infusion) regimen;	The Second Affiliated Hospital of Kunming Medical University	NULL	Pending	18	70	Both	Therapy Group:23;	Phase 1	China
2	NCT05369377 (ClinicalTrials.gov)	June 1, 2022	6/5/2022	Zanubrutinib and Eltrombopag as Second-line Treatment in Adults With Primary Immune Thrombocytopenia	Zanubrutinib and Eltrombopag as Second-line Treatment for Patients With Immune Thrombocytopenia: a Multicentre, Open-label,Randomised, Controlled, Phase 2 Trial	Immune Thrombocytopenia	Drug: Zanubrutinib;Drug: Eltrombopag	Peking University People's Hospital	Beijing Hospital;The Sixth Medical Center of PLA General Hospital;Beijing Aerospace General Hospital;Qilu Hospital of Shandong University;Beijing Tongren Hospital	Not yet recruiting	18 Years	70 Years	All	150	Phase 2	China

222. Primary nephrotic syndrome

---

Clinical trials : 310 /  Drugs : 295 - (DrugBank : 117) / Drug target genes : 63 - Drug target pathways : 194

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05707377 (ClinicalTrials.gov)	April 2023	23/1/2023	A Study to Evaluate the Safety and Efficacy of Zanubrutinib in Participants With Primary Membranous Nephropathy	A Phase 2/3, Multicenter, Randomized, Active-Controlled, Open-label Study to Evaluate the Efficacy and Safety of Zanubrutinib in Patients With Primary Membranous Nephropathy	Primary Membranous Nephropathy	Drug: Zanubrutinib;Drug: Tacrolimus	BeiGene	NULL	Not yet recruiting	18 Years	75 Years	All	282	Phase 2/Phase 3	NULL

300. IgG4-related disease

---

Clinical trials : 40 /  Drugs : 47 - (DrugBank : 21) / Drug target genes : 18 - Drug target pathways : 141

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04602598 (ClinicalTrials.gov)	August 1, 2022	20/10/2020	Zanubrutinib in Patients With IgG4-Related Disease	A Phase II, Single-Site, Open-Label Study of Zanubrutinib in Patients With IgG4-Related Disease	IgG4 Related Disease	Drug: Zanubrutinib 80 MG	Matthew C. Baker	Stanford University	Recruiting	18 Years	85 Years	All	10	Phase 2	United States

331. Idiopathic multicentric castleman disease

---

Clinical trials : 33 /  Drugs : 41 - (DrugBank : 21) / Drug target genes : 22 - Drug target pathways : 123

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04743687 (ClinicalTrials.gov)	January 1, 2021	3/2/2021	Zanuburutinib in Relapsed and Refractory iMCD: a Prospective, Single-center, Single-arm Trial	The Efficacy and Safety of Zanuburutinib in Relapsed and Refractory Idiopathic Multicentric Castleman Disease (iMCD): a Prospective, Single-center, Single-arm Trial	Idiopathic Multicentric Castleman's Disease	Drug: Zanubrutinib	Peking Union Medical College Hospital	NULL	Recruiting	18 Years	N/A	All	30	Phase 2	China

Back to top